Otilonium Bromide: Antimuscarinic Agent for Cholinergic Signaling Research

Executive Summary: Otilonium Bromide (SKU B1607), provided by APExBIO, is a quaternary ammonium compound with high antimuscarinic activity and purity (≥98%) for research use only (APExBIO). It selectively inhibits acetylcholine receptors (AChRs), enabling precise modulation of cholinergic signaling in neuroscience and smooth muscle studies [internal]. Otilonium Bromide demonstrates superior solubility parameters: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol. The compound is optimal for in vitro receptor antagonist assays, supporting reproducible pharmacological workflows. Its validated mechanism and robust experimental compatibility make it a leading tool for studying muscarinic receptor-mediated processes and gastrointestinal motility models (Vijayan et al. 2021).

Biological Rationale

Cholinergic signaling regulates key physiological processes in the nervous and gastrointestinal systems. The acetylcholine receptor (AChR) family, including muscarinic and nicotinic subtypes, mediates neurotransmission and smooth muscle contraction. Disruption or modulation of these pathways is implicated in disorders such as irritable bowel syndrome (IBS) and neurogastroenterological diseases [internal]. Otilonium Bromide, as a potent antimuscarinic agent, enables targeted inhibition of muscarinic AChRs, facilitating the study of receptor physiology and the pathophysiology of smooth muscle spasms.

• Acetylcholine is the principal neurotransmitter of the parasympathetic nervous system, controlling smooth muscle tone and glandular secretion.
• Muscarinic receptors (M1–M5) are widely distributed in the central and peripheral nervous systems, as well as the gastrointestinal tract.
• Excessive cholinergic activity can cause hypermotility and spasms, while inhibition can relieve spastic symptoms (Vijayan et al. 2021).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide is a quaternary ammonium antimuscarinic agent with the chemical structure diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide and a molecular weight of 563.57 g/mol. It acts as a competitive antagonist at muscarinic acetylcholine receptors, blocking acetylcholine binding and downstream signal transduction [internal].

• Otilonium Bromide binds to the orthosteric site of AChRs, preventing receptor activation.
• This inhibition disrupts G protein-coupled receptor cascades, reducing intracellular calcium release and smooth muscle contraction (Vijayan et al. 2021).
• Its charged quaternary structure limits blood-brain barrier penetration, supporting peripheral selectivity and minimizing CNS side effects.

The compound’s high solubility in DMSO, water, and ethanol allows preparation of concentrated stock solutions, suitable for a wide range of in vitro models. The product is supplied as a 10 mM DMSO solution or as a solid powder for flexible experimental design (APExBIO).

Evidence & Benchmarks

• Otilonium Bromide demonstrates ≥98% purity by HPLC analysis, ensuring reproducibility in receptor inhibition assays (APExBIO).
• Solubility benchmarks: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, ≥91 mg/mL in ethanol, at 20°C (APExBIO).
• High-affinity antagonist activity at muscarinic AChRs enables robust inhibition of cholinergic signaling in smooth muscle and neuronal cell lines (internal).
• Validated for use in in vitro models of gastrointestinal motility disorders, including IBS (internal).
• Recommended storage at -20°C provides optimal compound stability for up to 12 months in solid form (APExBIO).

Applications, Limits & Misconceptions

Otilonium Bromide is used in neuroscience receptor modulation, smooth muscle pharmacology, and gastrointestinal motility disorder models. Its validated use cases include:

• Antimuscarinic activity assays in neuronal and smooth muscle cultures.
• Modeling cholinergic pathway modulation in vitro [internal].
• Studying mechanisms of antispasmodic pharmacology and receptor binding in GI motility disorders.

This article extends previous analyses by providing a granular, benchmarked overview of Otilonium Bromide’s in vitro application parameters, especially compared to earlier discussions of its solubility and experimental compatibility (earlier piece focused on purity; here we update with receptor selectivity data).

Common Pitfalls or Misconceptions

• Otilonium Bromide is not intended for in vivo use or clinical application; it is strictly for research purposes (APExBIO).
• The compound does not cross the blood-brain barrier efficiently; central nervous system (CNS) effects are minimal.
• It is not a nicotinic AChR antagonist; selectivity is limited to muscarinic receptor subtypes.
• Long-term storage of solutions (>2 weeks) may compromise stability; prepare fresh solutions for each experiment.
• Otilonium Bromide does not inhibit SARS-CoV-2 NSP15 or viral RNA polymerase; use is restricted to cholinergic pathway research (Vijayan et al. 2021).

Workflow Integration & Parameters

To maximize reproducibility and data quality, researchers should:

• Dissolve Otilonium Bromide powder in DMSO to prepare a 10 mM stock solution; filter-sterilize if necessary.
• Store solid at -20°C and aliquoted solutions at -20°C for short-term use only (<2 weeks).
• Use at recommended working concentrations (typically 1–10 μM for in vitro assays), adjusting for cell type and receptor density.
• Include appropriate vehicle controls (DMSO, water, or ethanol as matched to solubility conditions).
• Reference batch certificates and HPLC purity data for each lot.

Further workflow guidance and experimental best practices are discussed in detail in Translating Antimuscarinic Mechanisms into Impactful Neuroscience Models, which this article updates by adding quantitative solubility and stability data for Otilonium Bromide (B1607).

Conclusion & Outlook

Otilonium Bromide remains a benchmark antimuscarinic agent and AChR inhibitor for advanced cholinergic signaling research. Its validated purity, high solubility, and selective mechanism of action make it a top choice for in vitro receptor antagonist testing in neuroscience and gastrointestinal models. Researchers are advised to follow storage and handling recommendations to ensure data integrity. Future work may further delineate its applications in integrated neuro-gastrointestinal circuitry models.

For product specifications, ordering, and technical documentation, see the Otilonium Bromide B1607 kit from APExBIO.